2014 EMD Serono Specialty Digest: Managing adherence programs are a sought-after service
The annual EMD Serono Specialty Digest, now in its 10th edition, is that manufacturer’s effort to survey trends among commercial and public health plans on how they are handling the administration of specialty drugs. Much of the discussion is the interaction between the plans and healthcare providers; the insights for manufacturers arise from the interplay of plans’ goals and how providers are meeting them.
The Digest tracks trends that have been progressing for some time: more specialty drugs are being handled as a pharmacy benefit and not a medical benefit (thus putting the drug cost out for review and monitoring); and formulary plans are being focused more closely on clinical outcomes. (Specific to oncology, 51% of plans have already, or plan to incorporate within the next 12 months, “clinical pathways” to standardize therapy. Also: 46% of plans include financial incentives to use generics and lower-cost drugs.) In what appears to be a brute-force approach to managing drug costs, 74% of formulary plans are composed with “preferred products regardless of mechanisms of action (MOAs)”—which implies that patient preference (or genetics) are of lesser significance. The other 24% “select at least one product from each MOA.” There are signs this might be changing: Currently, 14% of plans use an external vendor to manage companion diagnostics services, and that is projected to jump to 40% within the coming year.
A key question for pharma’s managed-care marketers is how pharmacy and therapeutics (P&T) committees make formulary decisions. According to the survey, nearly everyone (97%) wants to see head-to-head studies of comparable drugs. Three other highly ranked categories are conventional, randomized clinical trials; comparative effectiveness studies; and real-world evidence. Less-valued criteria are health economic data, retrospective data analysis, and non-randomized studies.
Some valuable tidbits from the survey:
The full survey, which was introduced this week at the Academy of Managed Care Pharmacy conference (Tampa), is available at EMD Serono’s website.
LogiPharma Unpacked: Highlights, Key Insights, and the Road to 2025
October 16th 2024In this special post-show episode, we sit down with Ryan Portela, Head of Production for LogiPharma, to reflect on the highlights and key takeaways from this year’s event. From attendee feedback to the most impactful sessions, Ryan shares insider insights and discusses how the momentum from 2024 will continue to shape the future of pharma supply chains. Plus, get a sneak peek into the exciting plans for LogiPharma's 20th Anniversary in 2025.